Merck Launched New Pergoveris Pen for Fertility Treatment
News Desk, News Nation 360 : Merck Specialties Pvt ltd, the healthcare business of Merck in India, launched Pergoveris® Pen for advanced infertility treatment in India. This launch emphasizes the company’s motive of fulfilling unmet medical needs by providing an improved, convenient, and ready-to-use combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency. Anandram Narasimhan, Managing Director, Merck Specialities Pvt Ltd said that multiple studies suggest that nearly 27.5 million Indian couples deal with infertility and are actively seeking fertility solutions, they strive to fulfil the dreams of such couples aspiring to become parents, by providing them with advanced treatment options. Their commitment to delivering an optimal range of products in the field of fertility medicines is a step forward with the latest addition of Pergoveris ready-to-use Pen, being an only premixed combination of recombinant human FSH (rhFSH) and recombinant human LH (rhLH) in the Indian markets. Infertility is no less than an endemic for Indians and is vastly dependent on a proper ovulation cycle. Ovulation is a process whereby a mature, fertilizable oocyte is released from the ovarian follicle. This process is the result of a well-defined sequence of events that includes the combined effect of the pituitary gonadotropins, FSH, and LH. Any functional disorder of the hypothalamic-pituitary-ovarian axis may lead to the absence of or infrequent ovulation, resulting in infertility. The new Pergoveris® Pen allows an improved treatment experience for patients with severe FSH and LH deficiency upon prescription by an IVF specialist.
Report : Anustup Kundu